Wednesday, 14 October 2015
Hall D1 Foyer (Floor 3) (Coex Convention Center)
Hyun Jung Jin, MD
,
Department of Internal Medicine, College of Medicine, Yeungnam University, Daegu, South Korea
Background: SP-D is a hydrophilic lectin and involves in a host defense mechanism against respiratory pathogens and modulates immune responses against bacteria or allergens. Purpose: The aim of this study was to evaluate serum SP-D level as a potential biomarker for aspirin-exacerbated respiratory disease (AERD) compared to aspirin tolerant asthma (ATA) patients. Subjects and methods: Ninety-three subjects with AERD, 172 ATA and 75 healthy controls were enrolled at Ajou University Hospital (Suwon, Korea). Serum SP-D levels were measured using commercially available ELISA kit. Results: The SP-D levels in sera of AERD patients were significantly lower than those of ATA and control groups. The ROC curve indicated that SP-D at 1755.82pg/ml can be an optimal cutoff value for predicting the phenotype of AERD with 64.3% sensitivity and 62.4% specificity. No associations were found with clinical parameters such as atopy, chronic rhino-sinusitis, eosinophilic/neutrophilic asthma or severe/non-severe asthma. A significant negative correlation was found between serum SP-D level and the fall of FEV1 (%) after inhaled lysine-ASA in asthmatic patients. Conclusion: These findings suggest that SP-D may involve in the pro-inflammatory response of airway mucosa which contribute to bronchoconstrictive response to inhaled ASA in AERD patients.